Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 26 results:
[ Συντάκτης] Τίτλος Τύπος Έτος Φίλτρα: Συντάκτης is Doumas, Michael [Clear All Filters]
Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes..
N Engl J Med. 378(10), 967.
(2018). Telmisartan for prevention of cardiovascular events..
N Engl J Med. 360(3), 302; author reply 303.
(2009). Gender differences in hypertension: myths and reality..
Curr Hypertens Rep. 15(4), 321-30.
(2013). Obstructive sleep apnea, hypertension, and fibrin clot properties: a novel pathogenetic link with cardiovascular disease?.
J Hypertens. 35(5), 950-952.
(2017). Renal sympathetic denervation: the jury is still out..
Lancet. 376(9756), 1878-80.
(2010). Renal nerve ablation for resistant hypertension: the dust has not yet settled..
J Clin Hypertens (Greenwich). 16(6), 399-400.
(2014). Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?.
J Clin Hypertens (Greenwich). 20(3), 469-471.
(2018). Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective..
J Hypertens. 30(5), 874-6.
(2012). Arterial Stiffness and Emerging Biomarkers: Still a Long Journey to Go..
Angiology. 66(10), 901-3.
(2015). Renal sympathetic denervation and systemic hypertension..
Am J Cardiol. 105(4), 570-6.
(2010). Editorial: interventional management of hypertension and cardiovascular disease: the beginning of a new era?.
Curr Vasc Pharmacol. 12(1), 2-3.
(2014). Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension..
J Am Heart Assoc. 6(11),
(2017). Management of erectile dysfunction: do not forget hypertension..
Arch Intern Med. 172(7), 597-8; discussion 598.
(2012). Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?.
Cardiology. 131(3), 186-8.
(2015). Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints..
Curr Pharm Des.
(2018). Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions..
Expert Opin Ther Targets. 13(4), 413-25.
(2009). Effects of hypertension and antihypertensive therapy on sexual function in the elderly: the jury is still out..
J Hypertens. 31(9), 1917-8.
(2013). Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?.
Angiology. 69(1), 5-9.
(2018). Renal sympathetic denervation in hypertension..
Curr Opin Nephrol Hypertens. 20(6), 647-53.
(2011). Screening for Primary Aldosteronism: Whom and How?.
J Clin Hypertens (Greenwich). 17(7), 547-8.
(2015). Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?.
J Clin Hypertens (Greenwich). 20(4), 634-636.
(2018). Interventional management of resistant hypertension..
Lancet. 373(9671), 1228-30.
(2009). Masked hypertension in untreated and treated patients with diabetes mellitus: attractive but questionable interpretations..
Hypertension. 62(4), e21.
(2013). Blood pressure and cardiovascular outcomes: a closer look..
Lancet. 389(10076), 1295-1296.
(2017). Benefits from treatment and control of patients with resistant hypertension..
Int J Hypertens. 2011, 318549.
(2010).